Welcome to our dedicated page for Cardiff Lexingto SEC filings (Ticker: CDIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Lexington Corporation (CDIX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory documents, along with AI-powered summaries to help interpret complex disclosures. As a Nevada-incorporated healthcare holding company and smaller reporting company, Cardiff Lexington files registration statements, current reports, and periodic reports that describe its operations, capital structure, and risks.
Investors can review Form S-1 filings, such as the registration statement filed in December 2025 in connection with a proposed public offering and planned uplisting of CDIX to The Nasdaq Capital Market. The S-1 includes detailed financial statements, risk factors, information on preferred and common stock, and the company’s description of its business as a targeted healthcare holding company focused on orthopedic, spine care, and pain management clinics through Nova Ortho and Spine, LLC.
Form 8-K current reports are also available, including filings that document material corporate events. For example, a January 2026 Form 8-K records the resignation of Daniel Thompson from the Board of Directors, notes that his departure was not due to any disagreement with the company, and confirms the appointment of Chief Executive Officer Alex Cunningham as Chairman of the Board. These filings provide authoritative detail on governance changes and other significant developments.
Through this page, users can track quarterly and annual reports (Forms 10-Q and 10-K, when filed) to analyze Cardiff Lexington’s revenue, gross profit, operating income, interest expense, mezzanine equity, preferred stock series, and accumulated deficit. AI-generated highlights help clarify key sections, such as segment information related to Nova Ortho and Spine, non-GAAP reconciliations referenced in earnings materials, and discussions of liquidity and capital resources.
In addition, the filings page surfaces insider and capital markets-related disclosures where applicable, allowing users to monitor how Cardiff Lexington manages its capital structure, including reverse stock splits and line-of-credit arrangements discussed in its public documents. Real-time updates from EDGAR, combined with AI explanations, make it easier to understand the implications of new filings for CDIX shareholders and prospective investors.
Cardiff Lexington (CDIX) reported Q3 2025 results. Revenue rose to $3,058,740 from $1,355,641 a year ago, lifting gross profit to $1,909,579. Operating income reached $643,279, but higher interest expense of $1,765,528 drove a net loss of $1,144,299. For the nine months, revenue was $8,763,314 with a net loss of $2,821,471.
The balance sheet shows cash of $232,033, accounts receivable of $20,699,999, and line of credit borrowings of $14,727,190 as of September 30, 2025. The company continues to record healthcare receivables and revenue at a settlement realization rate of 42%. Accumulated deficit was $76,533,799 and management disclosed substantial doubt about continuing as a going concern absent additional capital.
The company restated 2024 cash flows to reclassify $1,953,667 of non‑cash interest to operating activities, with no change to total cash flows. Common shares outstanding were 19,904,708 as of September 30, 2025; 19,954,708 were outstanding as of November 10, 2025.